Literature DB >> 29985849

Five Cases of Interstitial Pneumonitis Due to Gemcitabine and Nab-Paclitaxel Combination Treatment in Pancreatic Cancer Patients.

Yusuke Ogawa1, Eiichiro Suzuki, Rintaro Mikata, Shin Yasui, Mitsuhiro Abe, Yotaro Iino, Hiroshi Ohyama, Tetsuhiro Chiba, Toshio Tsuyuguchi, Naoya Kato.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29985849     DOI： 10.1097/MPA.0000000000001088

Source DB:  PubMed          Journal:  Pancreas        ISSN： 0885-3177            Impact factor:   3.327


× No keyword cloud information.
  3 in total

1.  A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer.

Authors:  Rikiya Hasegawa; Kosuke Okuwaki; Mitsuhiro Kida; Hiroshi Yamauchi; Yusuke Kawaguchi; Takaaki Matsumoto; Toru Kaneko; Eiji Miyata; Kazuho Uehara; Tomohisa Iwai; Masafumi Watanabe; Takahiro Kurosu; Hiroshi Imaizumi; Takashi Ohno; Wasaburo Koizumi
Journal:  Int J Clin Oncol       Date:  2019-07-15       Impact factor: 3.402

2.  Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties.

Authors:  Sungwoo Hong; Zhenghuan Fang; Hoi-Yun Jung; Jin-Ha Yoon; Soon-Sun Hong; Han-Joo Maeng
Journal:  Molecules       Date:  2018-10-11       Impact factor: 4.411

3.  Risk factors for interstitial lung disease induced by gemcitabine plus albumin-bound paclitaxel therapy in pancreatic ductal adenocarcinoma patients.

Authors:  Rikako Ueda; Naho Yamamoto; Yuki Hori; Kouji Yoshida; Koushiro Ohtsubo; Takeshi Terashima; Tsutomu Shimada; Yoshimichi Sai
Journal:  J Pharm Health Care Sci       Date:  2022-02-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.